Top

Published in:

01-03-2019 | Original Article

Evaluation of the effects of miRNAs in familial Mediterranean fever

Authors: Hacer Orsdemir Hortu, Emin Karaca, Betul Sozeri, Nesrin Gulez, Balahan Makay, Cumhur Gunduz, Tahir Atik, Ismihan Merve Tekin, Sevket Erbil Unsal, Ozgur Cogulu

Published in: Clinical Rheumatology | Issue 3/2019

Abstract

Familial Mediterranean fever (FMF) is an inherited autoinflammatory disorder that can result in attacks with accompanying recurrent episodes of fever, serositis, and skin rash. MiRNAs are demonstrated to be associated with a number of other diseases; however, no comprehensive study has revealed its association with FMF disease. The aim is to investigate the role of microRNAs in FMF. We included 51 patients with genetically diagnosed FMF who had clinical symptoms and 49 healthy volunteers. Fifteen miRNAs that were found to be associated with autoinflammatory diseases and have a part in immune response were evaluated. The expression levels of 11 miRNAs (miR-125a, miR-132, miR-146a, miR-155, miR-15a, miR-16, miR-181a, miR-21, miR-223, miR-26a, and miR-34a) in the patient group were significantly low, compared with the control group (p < 0.05). The patient group was analyzed and compared within itself, and the expression levels of 5 miRNAs (miR-132, miR-15a, miR-181a, miR-23b, miR-26a) in the patients who took colchicine seemed to have increased and levels of 5 miRNAs (miR-146a, miR-15a, miR-16, miR-26a, miR-34a) in the patients who took colchicine were significantly lower (p < 0.05). Furthermore, the attack patients were compared with the control group, and their expression levels of 4 miRNAs (miR-132, miR-15a, miR-21, miR-34a) were significantly lower (p < 0.05). Levels of 9 miRNAs (miR-132, miR-146a, miR-15a, miR-16, miR-181a, miR-21, miR-223, miR-26a, miR-34a) in non-attack patients decreased significantly (p < 0.05). Our study demonstrates that miRNAs could be effective in the pathogenesis of FMF.

Peru H, Altun B, Doğan M, Kara F, Elmaci AM, Oran B (2008) The evaluation of carotid intima-media thickness in children with familial Mediterranean fever. Clin Rheumatol 27(6):689–694. https://doi.org/10.1007/s10067-007-0764-1 CrossRefPubMed

Zadeh N, Getzug T, Grody WW (2011) Diagnosis and management of familial Mediterranean fever: integrating medical genetics in a dedicated interdisciplinary clinic. Genet Med 13(3):263–269. https://doi.org/10.1097/GIM.0b013e31820e27b1 CrossRefPubMed

Papin S, Cuenin S, Agostini L, Martinon F, Werner S, Beer HD, Grütter C, Grütter M, Tschopp J (2007) The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ 14(8):1457–1466. https://doi.org/10.1038/sj.cdd.4402142 CrossRefPubMed

Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L et al (2011) Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 34(5):755–768CrossRefPubMedPubMedCentral

de Torre-Minguela C, Mesa Del Castillo P, Pelegrín P (2017) The NLRP3 and pyrin inflammasomes: implications in the pathophysiology of autoinflammatory diseases. Front Immunol 8:43PubMedPubMedCentral

Ben-Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet 351(9103):659–364. https://doi.org/10.1016/S0140-6736(97)09408-7 CrossRefPubMed

Samuels J, Aksentijevich I, Torosyan Y, Centola M, Deng Z, Sood R, Kastner DL (1998) Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations and a survey of 100 American referrals to the National Institutes of Health. Medicine 77(4):268–297. https://doi.org/10.1097/00005792-199807000-00005 CrossRefPubMed

Heller H, Shoar E, Gafni J, Heller J (1961) Amyloidosis in FMF: an independent genetically determined character. Arch Intern Med 107(4):539–550. https://doi.org/10.1001/archinte.1961.03620040065007 CrossRefPubMed

Rogers DB, Shohat M, Petersen CM, Bickal J, Congleton J, Schwabe AD et al (1989) Familial Mediterranean fever in Armenians: autosomal recessive inheritance with high gene frequency. Am J Med Genet 34(2):168–172. https://doi.org/10.1002/ajmg.1320340206 CrossRefPubMed

10.

Ben-Chetrit E, Backenroth R (2001) Amyloidosis induced, end stage renal disease in patients with familial Mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis 60(2):146–149. https://doi.org/10.1136/ard.60.2.146 CrossRefPubMedPubMedCentral

11.

Mansour I, Delague V, Cazeneuve C, Dodé C, Chouery E, Pêcheux C, Medlej-Hashim M, Salem N, ElZein L, Levan-Petit I, Lefranc G, Goossens M, Delpech M, Amselem S, Loiselet J, Grateau G, Mégarbane A, Naman R (2001) Familial Mediterranean fever in Lebanon: mutation spectrum, evidence for cases in Maronites, Greek orthodoxes, Greek catholics, Syriacs and Chiites and for an association between amyloidosis and M694V and M694I mutations. Eur J Hum Genet 9(1):51–55. https://doi.org/10.1038/sj.ejhg.5200574 CrossRefPubMed

12.

Tekin M, Yalcinkaya F, Cakar N, Akar N, Misirlioglu M, Tastan H et al (2000) MEFV mutations in multiplex families with familial Mediterranean fever: is a particular genotype necessary for amyloidosis? Clin Genet 57(6):430–434CrossRefPubMed

13.

Daniel LK (1997) İntermittent and periodic arthritic syndromes. In: Kopman JK (ed) Arthritis and allied conditions: a textbook of rheumatology, 13 edn. Williams and Wilkins Comp., Philadelphia, pp 1279–1306

14.

Baykal Y, Saglam K, Yilmaz MI, Taslipinar A, Akinci SB, Inal A et al (2003) Serum sIL-2r, IL-6, IL-10 and TNF-alpha level in familial Mediterranean fever patients. Clin Rheumatol 22(2):99–101. https://doi.org/10.1007/s10067-002-0682-1 CrossRefPubMed

15.

Korkmaz C, Ozdogan H, Kasapcopur O, Yazıcı H (2002) Acute phase response in familial Mediterranean fever. Ann Rheum Dis 61(1):79–81. https://doi.org/10.1136/ard.61.1.79 CrossRefPubMedPubMedCentral

16.

Ben-Cherit E, Bergmann S, Sood R (2006) Mechanism of the antiinflammatory effect of colchicine in rheumatic diseases :a possible new outlook through microarray analysis. Rheumatology 45(3):274–282. https://doi.org/10.1093/rheumatology/kei140 CrossRef

17.

Álvarez-Errico D, Vento-Tormo R, Ballestar E (2017) Genetic and epigenetic determinants in autoinflammatory diseases. Front Immunol 22(8):318

18.

Bartel DP (2004) MiRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297. https://doi.org/10.1016/S0092-8674(04)00045-5 CrossRefPubMed

19.

Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843–854. https://doi.org/10.1016/0092-8674(93)90529-Y CrossRefPubMed

20.

Jackson RJ, Standart N (2007) How do miRNAs regulate gene expression? Sci STKE 1:367

21.

Cobb BS, Hertweck A, Smith J, O'Connor E, Graf D, Cook T, Smale ST, Sakaguchi S, Livesey FJ, Fisher AG, Merkenschlager M (2006) A role for Dicer in immune regulation. J Exp Med 203(11):2519–2527. https://doi.org/10.1084/jem.20061692 CrossRefPubMedPubMedCentral

22.

Muljo SA, Ansel KM, Kanellopoulou C, Livingston DM, Rao A, Rajewsky K (2005) Aberrant T cell differentiation in the absence of Dicer. J Exp Med 202(2):261–269. https://doi.org/10.1084/jem.20050678 CrossRefPubMedPubMedCentral

23.

Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885. https://doi.org/10.1002/art.1780401023 CrossRefPubMed

24.

Tone Y, Toma T, Toga A, Sakakibara Y, Wada T, Yabe M, Kusafuka H, Yachie A (2012) Enhanced exon 2 skipping caused by c.910G>A variant and alternative splicing of MEFV genes in two independent cases of familial Mediterranean fever. Mod Rheumatol 22(1):45–51. https://doi.org/10.3109/s10165-011-0461-4 CrossRefPubMed

25.

Jung SH, Young SS (2012) Power and sample size calculation for microarray studies. J Biopharm Stat 22(1):30–42. https://doi.org/10.1080/10543406.2010.500066 CrossRefPubMedPubMedCentral

26.

Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE et al (2008) Altered expression of MiRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 58(4):1001–1009. https://doi.org/10.1002/art.23386 CrossRefPubMed

27.

Faraoni I, Antonetti FR, Cardone J, Bonmassar E (2009) miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 1792(6):497–505. https://doi.org/10.1016/j.bbadis.2009.02.013 CrossRefPubMed

28.

Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK (2008) Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 10(4):R101. https://doi.org/10.1186/ar2493 CrossRefPubMedPubMedCentral

29.

Li X, Kroin JS, Kc R, Gibson G, Chen D, Corbett GT, Pahan K, Fayyaz S, Kim JS, van Wijnen AJ, Suh J, Kim SG, Im HJ (2013) Altered spinal miRNA-146a and the miRNA-183 cluster contribute to osteoarthritic pain in knee joints. J Bone Miner Res 28(12):2512–2522. https://doi.org/10.1002/jbmr.2002 CrossRefPubMedPubMedCentral

30.

Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP, Chen S, Shen N (2009) MiRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 60(4):1065–1075. https://doi.org/10.1002/art.24436 CrossRefPubMed

31.

Wang G, Tam LS, Li EK, Kwan BC, Chow KM, Luk CC et al (2010) Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. J Rheumatol 37(12):2516–2522. https://doi.org/10.3899/jrheum.100308 CrossRefPubMed

32.

Bauernfeind F, Rieger A, Schildberg FA, Knolle PA, Schmid-Burgk JL, Hornung V (2012) NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol 189(8):4175–4181. https://doi.org/10.4049/jimmunol.1201516 CrossRefPubMed

33.

Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, Liu ZG (2010) MiRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. Nat Immunol 11(9):799–805. https://doi.org/10.1038/ni.1918 CrossRefPubMedPubMedCentral

34.

Fulci V, Scappucci G, Sebastiani GD, Giannitti C, Franceschini D, Meloni F, Colombo T, Citarella F, Barnaba V, Minisola G, Galeazzi M, Macino G (2010) miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol 71(2):206–211. https://doi.org/10.1016/j.humimm.2009.11.008 CrossRefPubMed

35.

Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H et al (2010) Plasma and synovial fluid miRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 12:R86CrossRefPubMedPubMedCentral

36.

Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC (2012) MiRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alphainduced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A 109(20):7865–7870. https://doi.org/10.1073/pnas.1200081109 CrossRefPubMedPubMedCentral

37.

Zhao X, Tang Y, Qu B, Cui H, Wang S, Wang L, Luo X, Huang X, Li J, Chen S, Shen N (2010) MiRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum 62(11):3425–3435. https://doi.org/10.1002/art.27632 CrossRefPubMed

38.

Lashine YA, Seoudi AM, Salah S, Abdelaziz AI (2011) Expression signature of miRNA 181-a reveals its crucial role in the pathogenesis of paediatric systemic lupus erythematosus. Clin Exp Rheumatol 29(2):351–357PubMed

39.

Okuhara A, Nakasa T, Shibuya H, Niimoto T, Adachi N, Deie M, Ochi M (2012) Changes in miRNA expression in peripheral mononuclear cells according to the progression of osteoarthritis. Mod Rheumatol 22(3):446–457. https://doi.org/10.3109/s10165-011-0536-2 CrossRefPubMed

40.

Tufekci KU, Oner MG, Genc S, Genc K (2011) MiRNAs and multiple sclerosis. Autoimmun Dis 2011:1–27. https://doi.org/10.4061/2011/807426 CrossRef

41.

Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Shuja M et al (2013) Circulating miRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol 73(6):729–740. https://doi.org/10.1002/ana.23880 CrossRefPubMed

42.

Niederer F, Trenkmann M, Ospelt C, Karouzakis E, Neidhart M, Stanczyk J, Kolling C, Gay RE, Detmar M, Gay S, Jüngel A, Kyburz D (2012) Down-regulation of miRNA-34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis Rheum 64(6):1771–1779. https://doi.org/10.1002/art.34334 CrossRefPubMed

43.

Zhang R, Tian A, Wang J, Shen X, Qi G, Tang Y (2015) miR26a modulates Th17/Treg balance in the EAE model of multiple sclerosis by targeting IL6. NeuroMolecular Med 17(1):24–34. https://doi.org/10.1007/s12017-014-8335-5 CrossRefPubMed

44.

Zhu S, Pan W, Song X, Liu Y, Shao XR, Tang YJ et al (2012) The miRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB 2, TAB 3 and IKK-alpha. Nat Med 18(7):1077–1086. https://doi.org/10.1038/nm.2815 CrossRefPubMed

45.

Wada T, Toma T, Matsuda Y, Yachie A, Itami S, Taguchi Y et al (2017) Microarray analysis of circulating microRNAs in familial Mediterranean fever. Mod Rheumatol 6:1–18

46.

Latsoudis H, Mashreghi MF, Grün JR, Chang HD, Stuhlmüller B, Repa A, Gergiannaki I, Kabouraki E, Vlachos GS, Häupl T, Radbruch A, Sidiropoulos P, Doukoumetzidis K, Kardassis D, Niewold TB, Boumpas DT, Goulielmos GN (2017) Differential expression of miR-4520a associated with pyrin mutations in familial Mediterranean fever (FMF). J Cell Physiol 232(6):1326–1336. https://doi.org/10.1002/jcp.25602 CrossRefPubMed

Title: Evaluation of the effects of miRNAs in familial Mediterranean fever
Authors: Hacer Orsdemir Hortu
Emin Karaca
Betul Sozeri
Nesrin Gulez
Balahan Makay
Cumhur Gunduz
Tahir Atik
Ismihan Merve Tekin
Sevket Erbil Unsal
Ozgur Cogulu
Publication date: 01-03-2019
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 3/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3914-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Evaluation of treatment adherence in patients with Behçet’s disease: its relation to disease manifestations, patients’ beliefs about medications, and quality of life

The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors

Early canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene

Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities—comments on the article by Danve A & Deodhar A

Seasonal variation in the internet searches for gout: an ecological study

The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren’s syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage